With Claimed Perfecting Feature In Contents (e.g., Excipient, Lubricant, Etc.) Patents (Class 424/465)
  • Aqueous polymer dispersion based on N,N-diethylaminoethyl methacrylate, its preparation and use
    Patent number: 8790693
    Abstract: The present invention relates to a process for preparing an aqueous polymer dispersion by free-radical emulsion polymerization of a monomer mixture which comprises N,N-diethylaminoethyl methacrylate, to the polymer dispersion obtainable by this process, and to the use thereof.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: July 29, 2014
    Assignee: BASF SE
    Inventors: Maximilian Angel, Karl Kolter, Hartwig Voβ
  • CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER
    Publication number: 20140205659
    Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.
    Type: Application
    Filed: March 14, 2014
    Publication date: July 24, 2014
    Applicant: Forward Pharma A/S
    Inventors: Henrik NILSSON, Florian Schoenharting, Bemd W. Muller, Joseph R. Robinson
  • Controlled release and taste masking oral pharmaceutical composition
    Patent number: 8784888
    Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: July 22, 2014
    Assignee: Cosmo Technologies Limited
    Inventors: Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
  • Pharmaceutical preparation of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide
    Patent number: 8784887
    Abstract: The invention relates to a pharmaceutical preparation for oral administration comprising N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide or its hydrates and/or solvates, as well as an acid, a method for its production as well as the use of this preparation for the treatment and/or prophylaxis of diseases which are caused by herpes viruses, in particular diseases which are caused by herpes simplex viruses.
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: July 22, 2014
    Assignee: Aicuris GmbH & Co. KG
    Inventors: Tobias Laich, Katrin Liebelt
  • CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER
    Publication number: 20140199387
    Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.
    Type: Application
    Filed: March 14, 2014
    Publication date: July 17, 2014
    Applicant: Forward Pharma A/S
    Inventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
  • CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER
    Publication number: 20140199388
    Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.
    Type: Application
    Filed: March 14, 2014
    Publication date: July 17, 2014
    Applicant: Forward Pharma A/S
    Inventors: Henrik NILSSON, Florian Schoenharting, Bernd W. Mueller, Joseph R. Robinson
  • CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER
    Publication number: 20140199392
    Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.
    Type: Application
    Filed: March 14, 2014
    Publication date: July 17, 2014
    Applicant: Forward Pharma A/S
    Inventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
  • Oral disintegrating tablet
    Patent number: 8778392
    Abstract: An oral disintegrating tablet containing (1) D-mannitol, (2) an active ingredient, (3) one or more disintegrating agents selected from the group consisting of crospovidone and carmellose, and (4) one or more lubricants selected from the group consisting of sodium stearyl fumarate and sucrose esters of fatty acids. The oral disintegrating tablet of the present invention has some excellent properties of (1) allowing easy production in a common facility without necessitating a specialized pharmaceutical technique, (2) having an appropriate strength that does not breakdown in the process of distribution, (3) having a fast disintegrating ability in the oral cavity, and (4) also having excellent ingestion feel such as greatly reduced bitterness or gritty feel; therefore, the tablet can be suitably used as a dosage form that is suitable for aged individuals, children, and seriously ill patients.
    Type: Grant
    Filed: March 12, 2008
    Date of Patent: July 15, 2014
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Makoto Matsuoka, Hiroyuki Nishii, Maki Kawamura
  • Saccharide free, storage stable thyroid hormone active drug formulations and methods for their production
    Patent number: 8779000
    Abstract: Embodiments of the present invention provide pharmaceutical compositions in unit dosage form that comprise a therapeutically effective amount of levothyroxine sodium; an antioxidant in an amount sufficient to stabilize the levothyroxine sodium against oxidation; an amount of an alditol sufficient to stabilize the levothyroxine sodium; and at least two excipients selected from a filler, a binder, and a lubricant. Such compositions are free of added monosaccharide, disaccharide, and an oligosaccharide and are storage stable.
    Type: Grant
    Filed: July 20, 2013
    Date of Patent: July 15, 2014
    Inventors: Nilesh Parikh, William Hite
  • Multi-unit gastroretentive pharmaceutical dosage form comprising microparticles
    Patent number: 8778396
    Abstract: This invention relates to an orally administrable, gastroretentive pharmaceutical dosage form which contains at least one pharmaceutically active ingredient and at least one polymeric adjuvant. The adjuvant serves to retain the dosage form in a selected region of the gastrointestinal tract for sufficient time for the pharmaceutically active ingredient to be released and absorbed. Ideally the dosage form will contain two or more pharmaceutically active ingredients which are delivered to different regions of the gastrointestinal tract.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: July 15, 2014
    Assignee: University of the Witwatersrand, Johannesburg
    Inventors: Viness Pillay, Yahya Choonara, Caragh Murphy, Sarashnee Moonisami
  • CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER
    Publication number: 20140193495
    Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.
    Type: Application
    Filed: March 13, 2014
    Publication date: July 10, 2014
    Applicant: FORWARD PHARMA A/S
    Inventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
  • Solid Dosage Forms of Oleyl Phosphocholine
    Publication number: 20140193493
    Abstract: The present invention relates to solid dosage forms of oleyl phosphocholine (C18:1-PC), or OlPC, for oral administration. Further, the present invention relates to methods for the preparation of the present solid dosage forms and the use thereof as a medicament and especially a medicament for treatment of parasitic diseases, such as leishmaniasis, chagas and malaria, and cancer both in humans and animals. Specifically, the present invention relates to a solid dosage form comprising: 6 to 25 weight % of the solid dosage form oleyl phosphocholine; 20 to 35 weight % of the solid dosage form lactose; 35 to 50 weight % of the solid dosage form cellulose; 5 to 20 weight % of the solid dosage form croscarmellose; 1 to 10 weight % of the solid dosage form hydroxypropylmethyl cellulose; and 0.05 to 1 weight % of the solid dosage form of a lubricant.
    Type: Application
    Filed: November 21, 2011
    Publication date: July 10, 2014
    Applicant: DAFRA PHARMA RESEARCH & DEVELOPMENT BVBA
    Inventor: Bruno Jansen
  • MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION
    Publication number: 20140193494
    Abstract: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the coreswells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.
    Type: Application
    Filed: March 3, 2014
    Publication date: July 10, 2014
    Applicants: Paladin Labs Inc., Paladin Labs Europe Limited, Paladin Labs (Barbados) Inc.
    Inventors: Miloud Rahmouni, Angela Ferrada, Fouzia Soulhi, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Bobby-Ernst Boursiquot, Ali Bichara
  • INTRABUCCALLY RAPIDLY DISINTEGRATING TABLET AND A PRODUCTION METHOD OF THE TABLETS
    Publication number: 20140193496
    Abstract: An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter, the powder material including a sugar alcohol or a saccharide as main ingredient, each of which is first particle having an average particle diameter of not more than 30 ?m, by mixing thus obtained granulated material with an active ingredient and a disintegrant, and by compressing the mixture into a predetermined shape.
    Type: Application
    Filed: March 13, 2014
    Publication date: July 10, 2014
    Applicant: KYOWA HAKKO KOGYO CO., LTD.
    Inventors: Motohiro OHTA, Eiji HAYAKAWA, Kunio ITO, Sanji TOKUNO, Kiyoshi MORIMOTO, Yasushi WATANABE
  • TASTE-MASKED PHARMACEUTICAL COMPOSITIONS CONTAINING DICLOFENAC
    Publication number: 20140193497
    Abstract: A pharmaceutical composition is described which includes diclofenac as an active ingredient. The pharmaceutical composition further includes a (meth)acrylic polymer which has a specific solubility and/or a particular functional group in one polymer component.
    Type: Application
    Filed: April 19, 2013
    Publication date: July 10, 2014
    Applicant: Glatt AG
    Inventors: Frédéric Gerber, Marie Guhmann, Norbert Pöllinger
  • Pharmaceutical compositions for poorly soluble drugs
    Patent number: 8771739
    Abstract: The present invention provides a pharmaceutical composition of a practically insoluble drug, wherein the composition may be administered with food or without food. The composition may be in the form of a solid dispersion of the practically insoluble drug and a polymer having acidic functional groups, and the composition may in vitro form a suspension.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: July 8, 2014
    Assignee: Mayne Pharma International Pty Ltd
    Inventors: David Hayes, Angelo M. Morella
  • Process for the preparation of a medicament comprising vardenafil hydrochloride trihydrate
    Patent number: 8772292
    Abstract: The present invention relates to a process for the preparation of a medicament containing vardenafil hydrochloride trihydrate in solid form, in which vardenafil hydrochloride trihydrate is processed with suitable pharmaceutical auxiliaries at a temperature of from approx. 20° C. to approx. 45° C.
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: July 8, 2014
    Assignee: Ratiopharm GmbH
    Inventors: Yogesh S. Deshpande, Sandra Brueck, Julia Schulze Nahrup, Birgit Schnitter, Ganesh Gat, Javed Hussain
  • Method of manufacturing tablet
    Patent number: 8765176
    Abstract: A method of manufacturing a tablet containing coated granules comprising compressing the coated granules containing biologically active substance and having a temperature exceeding a room temperature, whereby the tablet can be prevented from rupture of a part of a coating film of the granules at the time of tablet compression.
    Type: Grant
    Filed: June 19, 2002
    Date of Patent: July 1, 2014
    Assignee: Takeda Pharmaceutical Campany Limited
    Inventors: Keiichi Yamamoto, Yoshio Mizukami, Daisuke Izutsu
  • Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
    Patent number: 8765173
    Abstract: A drug delivery system (DDS) for administration of a water soluble, cationic, and amphiphilic pharmaceutically active substance (API) which DDS comprises poorly water soluble nanoparticles formed by the API together with a Na-salt of N-all-trans-retinoyl cysteic acid methyl ester and/or a Na-salt of N-13-cis-retinoyl cysteic acid methyl ester. A pharmaceutical composition comprising such a DDS. Methods for preparation of such a DDS and such a pharmaceutical composition. Use of such a DDS and pharmaceutical composition for treatment of cancer.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: July 1, 2014
    Assignee: Ardenia Investments, Ltd.
    Inventors: Julian Aleksov, Igor Lokot
  • STABLE BENZIMIDAZOLE FORMULATION
    Publication number: 20140178469
    Abstract: A benzimidazole formulation which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual volatile excipients, including but not limited to residual alkalinizing agents and/or residual solvents.
    Type: Application
    Filed: October 15, 2013
    Publication date: June 26, 2014
    Applicant: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventors: Adel PENHASI, Avi AVRAMOFF, Maxim GOMBERG, Valerie AZOULAY
  • DISPERSIBLE TABLET
    Publication number: 20140178470
    Abstract: The present invention relates to a tablet comprising Nimorazole. In particular, the invention concerns a pharmaceutical composition or a tablet comprising Nimorazole or a pharmaceutically acceptable salt, for dispersion in water and administration via a tube to a patient with swallowing difficulties.
    Type: Application
    Filed: February 28, 2014
    Publication date: June 26, 2014
    Applicant: Azanta A/S
    Inventors: Nilesh Tanhaji Dumbre, Mahesh Mohanrao Bhadgale, Vardhaman Chandrakant Bafna
  • ABUSE-PROOFED DOSAGE FORM
    Publication number: 20140170079
    Abstract: The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form.
    Type: Application
    Filed: December 23, 2013
    Publication date: June 19, 2014
    Applicant: GRUENENTHAL GMBH
    Inventors: Elisabeth ARKENAU MARIC, Johannes BARTHOLOMAEUS, Heinrich KUGELMANN
  • BUPROPION HYDROBROMIDE POLYMORPHS
    Publication number: 20140170216
    Abstract: Polymorphous and amorphous forms of bupropion hydrobromide are described.
    Type: Application
    Filed: September 4, 2013
    Publication date: June 19, 2014
    Applicant: VALEANT INTERNATIONAL BERMUDA
    Inventors: Stefano Turchetta, Maurizio Zenoni
  • ORALLY DISINTEGRATING TABLETS AND METHODS OF MANUFACTURE
    Publication number: 20140170215
    Abstract: A tablet that rapidly disintegrates in the oral cavity comprising a compressed blend of rapidly dispersing microgranules prepared by granulating a sugar alcohol or a saccharide or a mixture thereof having an average particle size less than about 30 microns and a disintegrant, and a taste-masked microcapsule containing at least one drug, the microcapsule being prepared by granulating a pharmaceutically acceptable formulation comprising at least one drug in a therapeutically effective amount and at least one polymeric binder that improves resilience of the microgranules, wet milling the granulated mass, and microencapsulating the milled granules to provide microcapsules.
    Type: Application
    Filed: August 23, 2013
    Publication date: June 19, 2014
    Inventors: Gopi M. VENKATESH, Ken Kangyi Qian, Shyam Vangala, James M. Clevenger, Donald Guenther
  • Pharmaceutical composition comprising at least one active agent and a binder, which swells in an acidic media
    Patent number: 8753681
    Abstract: The invention relates to a pharmaceutical composition, which comprises at least one active agent and which further comprises a binder and/or a retarding agent, wherein the binder swells in an acidic medium, and the retarding agent retards the release of the active agent in an acidic or alkaline medium.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: June 17, 2014
    Assignee: LEK Pharmaceuticals D.D.
    Inventors: Igor Legen, Mateja Burjak
  • Dual release oral tablet compositions of dexlansoprazole
    Patent number: 8753682
    Abstract: Dual release oral tablet compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof and processes for the manufacture of the tablet composition and its use in the treatment of gastrointestinal disorders.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: June 17, 2014
    Assignee: Sanovel Ilac Sanayi ve Ticaret Anonim Sirketi
    Inventors: Umit Cifter, Ali Turkyilmaz, Ibrahim Murat Uzer, Alper Terkinli, Levent Oner
  • SUSTAINED RELEASE TABLET COMPRISING PREGABALIN THROUGH TWO-PHASE RELEASE-CONTROLLING SYSTEM
    Publication number: 20140161880
    Abstract: Provided is a sustained release tablet having two-phase release-controlling system, which consists of a first release-controlling phase comprising pregabalin or its salt and hydroxypropyl methylcellulose; and a second release-controlling phase comprising polyethylene oxide as a swelling polymer, the first release-controlling phase being homogeneously dispersed in the second release-controlling phase.
    Type: Application
    Filed: July 20, 2012
    Publication date: June 12, 2014
    Applicant: YUHAN CORPORATION
    Inventors: Jeong-Hoon Woo, Woon-Sook Na, Yang-Soo Jeong, Chang-Keun Hyun, Yoong-Sik Park
  • Controlled release oral dosage form
    Patent number: 8747898
    Abstract: A once a day bupropion salt formulation is disclosed.
    Type: Grant
    Filed: July 14, 2010
    Date of Patent: June 10, 2014
    Assignee: Andrx Pharmaceuticals, LLC
    Inventors: Boyong Li, Avinash Nangia, Chih Ming Chen, Xiu Xiu Cheng
  • Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration
    Publication number: 20140154313
    Abstract: The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a watersoluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound.
    Type: Application
    Filed: June 7, 2012
    Publication date: June 5, 2014
    Applicant: STI PHARMA, LLC
    Inventors: David F. Counts, Donald P. Cox, Anup K. Dam, Michael E. Stalhamer
  • NOVEL PHARMACEUTICAL COMPOSITION
    Publication number: 20140154316
    Abstract: Disclosed are novel pharmaceutical compositions containing N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, methods of using the compositions in therapy and processes for preparing the same.
    Type: Application
    Filed: December 11, 2013
    Publication date: June 5, 2014
    Applicant: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Douglas J. DeMARINI, Francisco Henriquez, Ngocdiep T. Le, Lihong Wang
  • Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
    Patent number: 8741342
    Abstract: The present invention relates to stable pharmaceutical compositions comprising entacapone, levodopa and carbidopa, or pharmaceutically acceptable salts or hydrates thereof. The invention also relates to processes for the preparation of such compositions.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: June 3, 2014
    Assignee: Wockhardt Research Centre
    Inventors: Sudhir Goswami, Mahesh Rameshwar Kalantri, Asif Mohammad, Narayanan Murali, Girish Kumar Jain
  • Modified release pharmaceutical compositions of dexlansoprazole
    Patent number: 8741345
    Abstract: Modified release oral pharmaceutical compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof in the form of a bilayer tablet and processes for the manufacture of the tablet composition and its use in the treatment of gastrointestinal disorders.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: June 3, 2014
    Assignee: Sanovel ILAC Sanayi Ve Ticaret Anonim Sirketi
    Inventors: Umit Cifter, Ali Turkyilmaz, Ibrahim Murat Uzer, Alper Terkinli, Levent Oner
  • Method and strand sintering equipment for continuous sintering of pelletized mineral material
    Patent number: 8726537
    Abstract: In a method and equipment for continuous sintering of pelletized mineral material, a partition wall (7, 8) arranged between two adjacent cooling chambers (4, 5; 5, 6) is in the height direction placed at a distance from the pellet bed (2), so that in between the partition wall (7, 8) and pellet bed (2), there is left a gap (s) that allows gas to flow between two adjacent cooling chambers (4, 5; 5; 6) through the gap (s) in order to equalize the pressure between the cooling chambers.
    Type: Grant
    Filed: August 3, 2010
    Date of Patent: May 20, 2014
    Assignee: Outotec Oyj
    Inventor: Marko Palander
  • Pharmaceutical compositions for treating or preventing pain
    Patent number: 8728522
    Abstract: Methods and compositions are provided which comprise effective amounts of one or more analgesics, such as hydrocodone or acetaminophen, and an antiemetic, such as promethazine, to treat a subject, including reducing or eliminating an adverse effect associated with the analgesics.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: May 20, 2014
    Assignee: Charleston Laboratories, Inc.
    Inventors: Paul Bosse, John Ameling, Bernard Schachtel, Ray Takigiku
  • Calcium carbonate granulation
    Patent number: 8728173
    Abstract: Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: May 20, 2014
    Assignee: Delavau L.L.C.
    Inventors: Kevin W. Lang, James W. Dibble, Raya Levin, Gregory B. Murphy
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20140134247
    Abstract: A stable formulation of telmisartan and hydrochlorothiazide having both substances in separate units is prepared, exhibiting exceptional stability when subjecting to stress conditions.
    Type: Application
    Filed: January 17, 2014
    Publication date: May 15, 2014
    Applicant: LEK PHARMACEUTICALS D.D.
    Inventors: Adnan Beso, Igor Legen, Sebastjan Reven
  • RAPID DISSOLVE TABLET COMPOSITIONS FOR VAGINAL ADMINISTRATION
    Publication number: 20140134246
    Abstract: Disclosed herein are pharmaceutically acceptable rapid dissolve vaginal tablet compositions comprising one or more active pharmaceutical ingredients suitable for therapy via topical action or systemic absorption, and methods of making and using such compositions.
    Type: Application
    Filed: November 1, 2013
    Publication date: May 15, 2014
    Applicant: Aptalis Pharmatech, Inc.
    Inventors: Gopi VENKATESH, Vijaya SWAMINATHAN, Jin-Wang LAI
  • Granulate comprising an oily substance, corresponding production method and tablet
    Patent number: 8722090
    Abstract: The invention relates to a process for the preparation of granules comprising an oily substance. It relates also to granules for a pharmaceutical formulation and to a tablet as a product of further processing.
    Type: Grant
    Filed: December 11, 2003
    Date of Patent: May 13, 2014
    Assignee: Hexal AG
    Inventors: Karin Klokkers, Ina Elfriede Otto, Heidemarie Edith Elfriede Meyer
  • Dosage form with impeded abuse
    Patent number: 8722086
    Abstract: A multiparticulate dosage form formulated to make misuse more difficult containing least one active substance with potential for misuse (A), at least one synthetic or natural polymer (C), optionally at least one natural, semi-synthetic or synthetic wax (D), at least one disintegrant (E) and optionally one or more additional physiologically compatible excipients (B), wherein the individual particles of the dosage form display a breaking strength of at least 500 N and a release of active substance of at least 75% after 45 minutes measured according to Ph.Eur. in the paddle mixer with sinker in 600 ml of aqueous buffer solution with a pH value of 1.2 at 37° C. and 75 rpm.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: May 13, 2014
    Assignee: Gruenenthal GmbH
    Inventors: Elisabeth Arkenau-Marić, Johannes Bartholomaeus, Iris Ziegler, Marcel Haupts
  • Method for production of orally rapidly disintegrating tablet comprising imidafenacin as active ingredient
    Patent number: 8722133
    Abstract: The present invention herein provides an imidafenacin-containing orally rapidly disintegrating tablet which is excellent in the photostability. The present invention comprises the steps of: (A) granulating imidafenacin together with starch to thus give a granulated product having an imidafenacin concentration ranging from 0.001 to 3% by mass and a starch concentration ranging from 40 to 99.999% by mass; (B) covering the granulated product prepared in the step (A) with a non-cellulosic coating agent; and (C) blending the granulated product obtained in the preceding step (B) with an excipient and a disintegrating agent and then forming the resulting mixture into a tablet according to the compression molding technique.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: May 13, 2014
    Assignee: Kyorin Pharmaceutical Co., Ltd.
    Inventors: Toshihiro Ishizaki, Yoshinobu Aoki
  • ORAL SOLID FORMULATION OF COMPOUND ANTI-TUBERCULAR DRUG AND PREPARATION METHOD THEREOF
    Publication number: 20140127294
    Abstract: Provided is an oral solid preparation of a compound anti-tubercular drug, wherein the active ingredients are rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride. The compound oral solid preparation is a coated tablet with coated core or a coated three-layer tablet, wherein the two active ingredients rifampicin and isoniazid do not contact directly. The compound oral solid preparation not only improves the stability of the compound preparation, but also improves the bioavailability of rifampicin.
    Type: Application
    Filed: April 10, 2012
    Publication date: May 8, 2014
    Applicant: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
    Inventors: Maojian Gu, Qilan Zheng, Chao Xu, Ning Li, Guixian Chen, Lan Zheng, Min Wang, Lintao Jiang
  • Pharmaceutical formulations containing an SGLT2 inhibitor
    Patent number: 8716251
    Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: May 6, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
  • Pharmaceutical composition comprising tramadol and ketoprofen in association
    Patent number: 8715726
    Abstract: The present invention relates to a pharmaceutical composition comprising a combination of active principles. More specifically: a stable pharmaceutical composition comprising a combination of tramadol and ketoprofen. Furthermore, a combination in solid form in which the active principles are vehicled in pharmaceutical forms and/or products that prevent contact between them. Complementarily, the present invention also relates to the combined use of ketoprofen and tramadol in the preparation of an oral medicine useful for relieving pain as well as a method for relieving pain with an oral pharmaceutical composition comprising a combination of tramadol and ketoprofen.
    Type: Grant
    Filed: January 28, 2008
    Date of Patent: May 6, 2014
    Assignee: Eurofarma Laboratories S.A.
    Inventors: Dante Alario Junior, Henry Jun Suzuki
  • Compositions of quaternary ammonium compounds containing bioavailability enhancers
    Patent number: 8709476
    Abstract: An oral pharmaceutical dosage form with enhanced gastrointestinal permeability, comprising a therapeutic quaternary ammonium compound together with an organic acid.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: April 29, 2014
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventor: Argaw Kidane
  • Pharmaceutical dosage form
    Patent number: 8709477
    Abstract: This invention relates to a oral pharmaceutical formulation for methylphenidate or its analogs, derivatives, isomers or enantiomers, including d-threo-methylphenidate.
    Type: Grant
    Filed: August 13, 2010
    Date of Patent: April 29, 2014
    Assignee: Kremers Urban Pharmaceuticals, Inc`
    Inventors: Dirk Kramer, Helene Rey, Mathias Scheer
  • GASTRORESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN
    Publication number: 20140112987
    Abstract: The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.
    Type: Application
    Filed: October 2, 2013
    Publication date: April 24, 2014
    Applicant: ALFA WASSERMANN S.P.A.
    Inventors: Giuseppe Claudio VISCOMI, Ernesto PALAZZINI, Villiam ZAMBONI, Maria Rosaria PANTALEO
  • Metformin glycinate salt for blood glucose control
    Patent number: 8703183
    Abstract: The present invention relates to metformin glycinate salt and pharmaceutical compositions thereof for the treatment of diabetes mellitus. The method includes administration of the metformin glycinate salt by various routes selected from oral, intravenous injectable, intramuscular injectable, nasal, intraperitoneal, or sublingual, in order to achieve a reduction in blood glucose levels. The invention further relates to the synthesis of a new 1,1-dimethylbiguanide glycinate salt, called Metformin Glycinate. The resulting salt exhibits advantages over other metformin salts. These advantages are due, in the first place, to the fact that the glycine counterion exhibits hypoglycemic effects by itself. Moreover, the salt exhibits more rapid absorption, reaching higher plasma concentrations than those produced with metformin hydrochloride.
    Type: Grant
    Filed: December 24, 2010
    Date of Patent: April 22, 2014
    Assignee: Laboratorios Silanes S.A. de C.V.
    Inventor: Jose Manuel FranciscoOchoa Lara
  • PHARMACEUTICAL FORMULATIONS OF PILOCARPINE
    Publication number: 20140105976
    Abstract: Disclosed herein are pharmaceutical compositions comprising at least one minitablet, where the minitablet comprises a core, comprising pilocarpine, or a pharmaceutically acceptable salt thereof; and a coating layer comprising a coating polymer.
    Type: Application
    Filed: October 11, 2013
    Publication date: April 17, 2014
    Applicant: THERAVIDA, INC.
    Inventors: Mehdi PABORJI, Robert V. TUOHY, Stephen P. LEVINE, Dana E. MOSESON, Nicolas D. KIRKLAND
  • Solid dosage form of coated bisphosphonate particles
    Patent number: 8697124
    Abstract: A solid dosage form comprises coated particles of bisphosphonate or a pharmaceutically acceptable analogue or derivative thereof.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: April 15, 2014
    Assignee: Arrow International Limited
    Inventors: Peter Persicaner, Craig Judy
  • Tablet preparation without causing a tableting trouble
    Patent number: 8697125
    Abstract: The present invention provides a tablet without causing a tableting trouble, which is superior in the tablet formability, dissolution property of pharmaceutically active ingredient, and the like.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: April 15, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Akihiko Ono, Shigeyuki Marunaka, Makoto Fukuta